GI
TRIB

GAMMA Investing’s Trinity Biotech TRIB Stock Holding History

GAMMA Investing’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-643
Closed -$367 – 3886
2025
Q1 		$367 Sell
643
-12,646
-95% -$9.98K ﹤0.01% 3715
2024
Q4 		$11.7K Buy
+13,289
New +$17.8K ﹤0.01% 2529

Other funds holding TRIB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return

GAMMA Investing's TRIB Position: Q2 2025 in Review

GAMMA Investing sold out of Trinity Biotech (TRIB) in Q2 2025, closing a stake of 643 shares — an estimated $367 sold.

GAMMA Investing first reported a position in TRIB in Q4 2024 and held it in 2 quarters. The position peaked at $11.7K in Q4 2024. 25 funds tracked by Wall St. Rank hold TRIB as of Q2 2025.

  • GAMMA Investing reported no remaining Trinity Biotech position as of Q2 2025 after selling out during the quarter.
  • GAMMA Investing sold 643 Trinity Biotech shares in Q2 2025, an estimated $367.
  • GAMMA Investing first reported a position in Trinity Biotech in Q4 2024 and held it in 2 quarters.
  • GAMMA Investing's Trinity Biotech position peaked at $11.7K in Q4 2024.
  • 25 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2025.

Based on GAMMA Investing's 13F filing for Q2 2025, filed 14 Jul 2025.